Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Cytarabine 7Daunorubicin 5Azacitidine 5venetoclax 3Decitabine 3ivosidenib 2decitabine and cedazuridine drug combination 2cedazuridine 2Mitoxantrone 2Idarubicin 2Etoposide 2treosulfan 1tagraxofusp 1revumenib 1quizartinib 1olutasidenib 1glasdegib 1gilteritinib 1fludarabine 1etoposide phosphate 1enasidenib 1cc-486 1Midazolam 1Itraconazole 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Drug Therapy 1Cobicistat 1CPX-351 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Myeloid, Acute × Mitoxantrone × Clear all
NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Astellas Pharma Inc

Phase 3 Completed
371 enrolled 36 charts 2 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00372593 2021-03-24

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Children's Oncology Group

Phase 3 Completed
1,070 enrolled 18 charts 1 FDA
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡